<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PCH</journal-id>
<journal-id journal-id-type="hwp">sppch</journal-id>
<journal-title>World Journal for Pediatric and Congenital Heart Surgery</journal-title>
<issn pub-type="ppub">2150-1351</issn>
<issn pub-type="epub">2150-0136</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2150135112438107</article-id>
<article-id pub-id-type="publisher-id">10.1177_2150135112438107</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Plastic Bronchitis in Patients With Fontan Physiology: Review of the Literature and Preliminary Experience With Fontan Conversion and Cardiac Transplantation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>LaRue</surname>
<given-names>Madeleine</given-names>
</name>
<degrees>BA</degrees>
<xref ref-type="aff" rid="aff1-2150135112438107">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gossett</surname>
<given-names>Jeffrey G.</given-names>
</name>
<degrees>MD, FAAP</degrees>
<xref ref-type="aff" rid="aff2-2150135112438107">2</xref>
<xref ref-type="corresp" rid="corresp1-2150135112438107"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stewart</surname>
<given-names>Robert D.</given-names>
</name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="aff3-2150135112438107">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Backer</surname>
<given-names>Carl L.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff4-2150135112438107">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mavroudis</surname>
<given-names>Constantine</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-2150135112438107">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jacobs</surname>
<given-names>Marshall L.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-2150135112438107">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-2150135112438107"><label>1</label>Case Western Reserve University School of Medicine, Cleveland, OH, USA</aff>
<aff id="aff2-2150135112438107"><label>2</label>Division of Pediatric Cardiology, Children’s Memorial Hospital, Chicago, IL, USA</aff>
<aff id="aff3-2150135112438107"><label>3</label>Department of Congenital Heart Surgery, Cleveland Clinic Children’s Hospital, Center for Pediatric and Adult Congenital Heart Disease, Cleveland, OH, USA</aff>
<aff id="aff4-2150135112438107"><label>4</label>Department of Surgery, Division of Cardiovascular-Thoracic Surgery, Children’s Memorial Hospital, Chicago, IL, USA</aff>
<aff id="aff5-2150135112438107"><label>5</label>Congenital Heart Institute, Walt Disney Pavilion, Florida Hospital for Children, Orlando, FL, USA</aff>
<author-notes>
<corresp id="corresp1-2150135112438107">Jeffrey Gossett, Division of Pediatric Cardiology, Children’s Memorial Hospital M/C 22, Northwestern University’s Feinberg School of Medicine, 2300 Children’s Plaza, Chicago, IL 60614, USA Email: <email>jgossett@childrensmemorial.org</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>3</issue>
<fpage>364</fpage>
<lpage>372</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>11</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>1</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">World Society for Pediatric and Congential Heart Surgery</copyright-holder>
</permissions>
<abstract>
<p>Plastic bronchitis is a rare, life-threatening condition characterized by the formation of mucofibrinous casts within the pulmonary bronchi. In patients with congenital heart disease, it is most frequently observed in single ventricular anatomies after Fontan palliation. The pathophysiology of plastic bronchitis remains unknown, and a consistently effective treatment strategy has yet to be identified. We report two cases of plastic bronchitis in patients with Fontan physiology. The first was treated with Fontan conversion and, despite encouraging short-term results, experienced recurrence of cast formation seven months postoperatively. The second underwent cardiac transplantation and has been free of bronchial casts for over one year. In addition, we explore the similarities between plastic bronchitis and protein-losing enteropathy, considering theories of their pathophysiologic mechanisms and reports of mutually effective treatment strategies. We propose that bronchial cast formation may result from the confluence of genetic makeup, inflammation, and the Fontan physiology and conclude that further investigation into therapies directed at these factors is merited.</p>
</abstract>
<kwd-group>
<kwd>plastic bronchitis</kwd>
<kwd>bronchial casts</kwd>
<kwd>congenital heart disease</kwd>
<kwd>single ventricle anatomy</kwd>
<kwd>Fontan conversion</kwd>
<kwd>cardiac transplantation</kwd>
<kwd>protein-losing enteropathy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2150135112438107">
<title>Introduction</title>
<p>For most patients with a functionally univentricular heart, the Fontan operation offers the best palliation available.<sup>
<xref ref-type="bibr" rid="bibr1-2150135112438107">1</xref>
</sup> The procedure creates a circulation in which systemic venous blood bypasses the ventricular chamber on its way to the pulmonary vasculature, enabling the systemic and pulmonary circulations to flow in series, driven by the single ventricle. This leads to a reduction in ventricular volume work and an improvement in systemic oxygenation.<sup>
<xref ref-type="bibr" rid="bibr2-2150135112438107">2</xref>
</sup> However, lack of a pumping chamber to drive blood into the pulmonary vasculature may lead to chronically elevated systemic venous pressures and restrict the ability to augment cardiac output.<sup>
<xref ref-type="bibr" rid="bibr3-2150135112438107">3</xref>
</sup> This unique physiologic state is associated with a variety of long-term complications, including ventricular dysfunction, atrial arrythmias, thromboemboli, hypoxemia, recurrent effusions, hepatic dysfunction, protein-losing enteropathy (PLE), and plastic bronchitis.<sup>
<xref ref-type="bibr" rid="bibr3-2150135112438107">3</xref>
</sup>
</p>
<p>Plastic bronchitis is a rare condition characterized by the acute formation of thick, mucofibrinous casts within the pulmonary bronchi.<sup>
<xref ref-type="bibr" rid="bibr4-2150135112438107">4</xref>
</sup> Casts vary in size from small plugs that can be expectorated to large branching structures that fill the tracheobronchial tree.<sup>
<xref ref-type="bibr" rid="bibr4-2150135112438107">4</xref>
</sup> Depending on the extent of cast formation, patients may present with symptoms ranging from a productive cough and mild dyspnea to severe obstructive respiratory distress.<sup>
<xref ref-type="bibr" rid="bibr5-2150135112438107">5</xref>
</sup> Diagnosis depends on the identification of casts that are expelled or visualized during bronchoscopy.<sup>
<xref ref-type="bibr" rid="bibr6-2150135112438107">6</xref>
</sup> In cases of acute respiratory failure, rigid bronchoscopy is often necessary to facilitate cast removal and prevent asphyxiation.<sup>
<xref ref-type="bibr" rid="bibr7-2150135112438107">7</xref>
</sup> Strategies to resolve or manage plastic bronchitis in the long term are largely based on anecdotal success and none have been proven effective in protocol-driven prospective trials.</p>
<p>The pathophysiology of plastic bronchitis in patients with Fontan physiology is unknown, contributing to the challenge of identifying effective treatment modalities. However, it seems likely that the hemodynamics associated with the Fontan circulation play a role, making surgical procedures that seek to improve the hemodynamic state potentially viable treatment options. We describe the occurrence of plastic bronchitis in two patients with Fontan physiology. The first was treated with Fontan conversion and, despite encouraging short-term results, experienced recurrence of plastic bronchitis seven months postoperatively. The second was treated with cardiac transplantation and has been free of bronchial casts for over one year. We also review the extant theories on the pathophysiology of plastic bronchitis and assess potential treatment strategies for this condition in the Fontan population.</p>
</sec>
<sec id="section2-2150135112438107">
<title>Case Study 1</title>
<p>A boy born with an unbalanced atrioventricular (AV) canal defect and hypoplastic right ventricle underwent a superior cavopulmonary anastomosis (bidirectional Glenn) and annuloplasty of the left AV valve in infancy. At age three, his left AV valve was replaced with a 27 mm prosthesis (St. Jude Medical, St. Paul, MN), and he received an atrial pacemaker for sick sinus syndrome. At almost four years of age, he underwent a lateral tunnel completion Fontan procedure without complications. He was then well until age 17, when he presented with moderate stenosis of the prosthetic mitral valve and a persistent cough associated with the expectoration of bronchial casts, leading to a diagnosis of plastic bronchitis. Pathological examination of the casts revealed them to be mucofibrinous and interspersed with inflammatory cells and alveolar macrophages. On cardiac catheterization, he was found to have a gradient of 9 to 12 mm Hg across the prosthetic AV valve and an unobstructed Fontan pathway with mean Fontan pressures of 19 mm Hg. Various medications were administered to alleviate cast production, including albuterol, oral clarithromycin, and acetylcysteine. However, expectoration of bronchial casts continued, especially during the fall and winter months, and multiple bronchoscopies were required for cast removal.</p>
<p>Fontan conversion with left AV valve replacement and cardiac transplantation were considered as treatment modalities, and the former was chosen on the basis that improved hemodynamics might alleviate the plastic bronchitis. Accordingly, at age 18, the patient underwent conversion from lateral tunnel to extracardiac total cavopulmonary connection with right-sided Maze procedure, replacement of the St Jude mitral prosthesis with Perimount mitral bioprosthesis, and replacement of the original pacemaker with a dual chamber, antitachycardia, Medtronic pacemaker. He was discharged with aerosolized acetylcysteine to be used as therapeutic intervention in the event of suspected cast recurrence.</p>
<p>For six months, he experienced no evidence of recurrence of his plastic bronchitis. At seven months, he coughed up a small blood-tinged cast, but this appeared to be an isolated event. Fifteen months after the operation, on arrival in a tropical climate for vacation, the patient experienced a relapse of respiratory symptoms that lasted for five days. Two additional, self-limited episodes arose in subsequent weeks, but otherwise the patient remained well. Two years after the operation, however, he entered a state of chronic bronchial cast production, with episodes of dry cough and cast expectoration occurring every five to seven days and lasting for approximately five days. Multiple episodes required bronchoscopic cast removal. Cardiac catheterization at this time revealed a mean gradient of 9 mm Hg across the prosthetic AV valve and an unobstructed Fontan pathway with mean Fontan pressures of 22 to 23 mm Hg. His chronic disease state persisted for three months but resolved soon after. Of note, the patient’s family identified a temporal relationship between the patient’s history of plastic bronchitis symptoms and his brother’s allergy symptoms. It has been two and a half years since the patient underwent Fontan conversion, and he continues to experience recurrences of plastic bronchitis, though apart from this he is generally in good health.</p>
</sec>
<sec id="section3-2150135112438107">
<title>Case Study 2</title>
<p>A girl born with an unbalanced AV canal defect, hypoplastic left ventricle with bilateral superior vena cava and malposed great vessels with pulmonary atresia underwent placement of a modified Blalock–Taussig shunt with left pulmonary arterioplasty as a neonate. At four months of age, she underwent a bilateral bidirectional Glenn procedure with right pulmonary arterioplasty which was complicated by prolonged pleural effusions. At almost three years of age, she underwent a preoperative catheterization which was notable for good systolic function, end-diastolic pressures of 6 mm Hg, superior vena cava and pulmonary artery pressures of 9 to 11 mm Hg, and systemic cardiac output of 5.1 L/min per m<sup>2</sup>. She then underwent an extracardiac Fontan with an #18 Gore-tex tube graft, right and main pulmonary arterioplasty, as well as cryoablation of an accessory AV node, and placement of atrial and ventricular epicardial bipolar pacing leads. This procedure was again notable for prolonged pleural effusions which were treated with low-fat diet but failed to respond, leading to a chemical pleurodesis two months after the Fontan. Due to the persistence of these effusions and chronic nonproductive cough, she was referred to the cardiac catheterization laboratory for a full hemodynamic evaluation.</p>
<p>On induction of anesthesia for the catheterization, she was noted to have very poor pulmonary compliance, and a bronchoscopy was performed at which time an extremely large and occlusive bronchial cast was removed. The remainder of the catheterization was notable for Fontan pressures of 10 to 14 mm Hg, with a ventricular end diastolic pressure of 7 mm Hg and cardiac output of 3.4 L/min per m<sup>2</sup>. Pathological examination of the cast revealed it to be composed of fibrinous material, mucin, macrophages, and neutrophils. Various medications were administered to alleviate cast production including bronchodilators, oral and inhaled steroids, inhaled dornase alfa, diuretics, sildenafil, and extensive chest physiotherapy.</p>
<p>Despite these interventions, frequent expectoration of bronchial casts continued with multiple episodes of complete occlusion of her right bronchus and need for bronchoscopic removal of the casts. At approximately 11 months post-Fontan, therefore, the decision was made to take down the Fontan and revert to a bilateral bidirectional Glenn physiology with the intent to diminish the total flow through the lungs and increase cardiac output. This intervention was uneventful, but she continued to have multiple episodes of life-threatening cast formation. She was therefore listed for cardiac transplantation.</p>
<p>After approximately three months on the waiting list, with ongoing cast formation every one to two weeks, she underwent a uncomplicated orthotopic heart transplantation. Subsequent to the transplantation, she was tapered off of her pulmonary regimen and there was no recurrence of plastic bronchitis, with no further casts produced. Of note, due to some mild right ventricular dysfunction of her new heart, her central venous pressures remained elevated with means of 10 to 16 mm Hg for approximately 6 months posttransplantation. She is now over 18 months out from transplantation, with durable resolution of her plastic bronchitis, leading to the hope that this represents a cure.</p>
</sec>
<sec id="section4-2150135112438107">
<title>Discussion</title>
<p>Plastic bronchitis is associated with several disorders, including bronchopulmonary infections and diseases involving mucous hypersecretion, but it is particularly serious in patients with palliated congenital heart disease (CHD).<sup>
<xref ref-type="bibr" rid="bibr6-2150135112438107">6</xref>
</sup> In a retrospective review of children with plastic bronchitis, Brogan et al<sup>
<xref ref-type="bibr" rid="bibr6-2150135112438107">6</xref>
</sup> found that patients with underlying cardiac conditions (40%) experienced the highest incidence of life-threatening events (41%) and the greatest mortality (29%) related to cast production. Additionally, these investigators noted that deaths among patients with CHD were sudden in nature compared to deaths in non-CHD patients, presumably due to the seriousness of pulmonary obstruction in patients with single ventricular physiology.</p>
<sec id="section5-2150135112438107">
<title>Histology</title>
<p>The histological compositions of casts in patients with underlying pulmonary disease and those with palliated CHD are generally different, suggesting potential differences in the pathophysiological mechanisms of cast formation. According to a system proposed by Seear et al,<sup>
<xref ref-type="bibr" rid="bibr4-2150135112438107">4</xref>
</sup> casts may be classified as either inflammatory or acellular. Inflammatory casts are composed mainly of fibrin and dense cellular infiltrates rich in eosinophils. These casts are primarily observed in patients with bronchopulmonary infections, such as tuberculosis and bacterial pneumonia, or inflammatory and allergic diseases of the lung, such as asthma and cystic fibrosis. Often, inflammatory casts follow an acute course, resolving with airway clearance, inhaled steroids, and therapy aimed at the underlying condition.<sup>
<xref ref-type="bibr" rid="bibr4-2150135112438107">4</xref>
</sup>
</p>
<p>Acellular casts consist primarily of mucin and typically contain little fibrin or inflammatory infiltrate<sup>
<xref ref-type="bibr" rid="bibr4-2150135112438107">4</xref>
</sup>; however, some may have a chylous composition, characterized by the presence of lipids and lymphocytes.<sup>
<xref ref-type="bibr" rid="bibr8-2150135112438107">8</xref>
</sup> Such casts are seen almost exclusively in patients with palliated CHD,<sup>
<xref ref-type="bibr" rid="bibr4-2150135112438107">4</xref>
</sup> particularly in those who have undergone a Fontan operation.<sup>
<xref ref-type="bibr" rid="bibr6-2150135112438107">6</xref>
</sup> Numerous medical and surgical therapies have been employed to reduce the formation of acellular casts but their success has been limited. As a result, plastic bronchitis in these patients tends to be chronic<sup>
<xref ref-type="bibr" rid="bibr4-2150135112438107">4</xref>
</sup> and treatment is generally more challenging.</p>
</sec>
<sec id="section6-2150135112438107">
<title>Pathophysiology</title>
<sec id="section7-2150135112438107">
<title>Theories of bronchial cast formation</title>
<p>The pathophysiologic basis of both inflammatory and acellular cast formation is unknown, and mechanisms leading to the onset of plastic bronchitis in Fontan patients are especially unclear. With regard to the latter, however, several theories have been proposed. The Fontan physiology is generally thought to be an important contributing factor.<sup>
<xref ref-type="bibr" rid="bibr6-2150135112438107">6</xref>,<xref ref-type="bibr" rid="bibr9-2150135112438107">9</xref>,<xref ref-type="bibr" rid="bibr10-2150135112438107">10</xref>
</sup> Reduced cardiac output has been implicated as a potential cause in case reports describing the resolution of plastic bronchitis after fenestration<sup>
<xref ref-type="bibr" rid="bibr11-2150135112438107">11</xref>
<xref ref-type="bibr" rid="bibr12-2150135112438107"/>–<xref ref-type="bibr" rid="bibr13-2150135112438107">13</xref>
</sup> or implantation of an atrial pacemaker.<sup>
<xref ref-type="bibr" rid="bibr14-2150135112438107">14</xref>
</sup> However, as with our second case, not all Fontan patients with plastic bronchitis demonstrate a particularly low cardiac output,<sup>
<xref ref-type="bibr" rid="bibr15-2150135112438107">15</xref>
</sup> and the restoration of cardiac output through fenestration or Fontan takedown in some has been an unsuccessful treatment strategy,<sup>
<xref ref-type="bibr" rid="bibr16-2150135112438107">16</xref>,<xref ref-type="bibr" rid="bibr17-2150135112438107">17</xref>
</sup> indicating a causal mechanism more complex than reduced cardiac output alone.</p>
<p>Elevated systemic venous pressure has also been described as a potential contributor. Languepin et al<sup>
<xref ref-type="bibr" rid="bibr9-2150135112438107">9</xref>
</sup> hypothesize that systemic venous hypertension may obstruct lymphatic drainage from the thoracic duct, leading to the dilation of pulmonary lymphatics, endobronchial lymph leakage, and subsequent cast formation. This theory is especially plausible for cases in which bronchial casts demonstrate a chylous character and is supported by the resolution of plastic bronchitis in two Fontan patients upon ligation of the thoracic duct.<sup>
<xref ref-type="bibr" rid="bibr18-2150135112438107">18</xref>
</sup> Yet, the majority of casts observed in Fontan patients are not explicitly chylous,<sup>
<xref ref-type="bibr" rid="bibr8-2150135112438107">8</xref>
</sup> and thoracic duct ligation has failed to prevent the recurrence of cast formation in at least one patient.<sup>
<xref ref-type="bibr" rid="bibr19-2150135112438107">19</xref>
</sup> Furthermore, in our patient who underwent cardiac transplantation, systemic venous pressures were actually higher for a period of time after her transplantation than they had been prior to transplant. Despite this, she had resolution of cast formation, which argues that this mechanism is not in itself adequate to explain the production of bronchial casts.</p>
<p>Perhaps more relevant to cases that demonstrate casts of a classic mucinous composition are theories involving mucous hypersecretion. Seear et al<sup>
<xref ref-type="bibr" rid="bibr4-2150135112438107">4</xref>
</sup> suggest that mucous hypersecretion in response to elevated pulmonary venous pressures may be responsible for acellular cast formation; however, this has been disputed, given that the Fontan circulation is not typically characterized by elevated pulmonary venous pressure and that several diseases characterized by pulmonary hypertension do not give rise to plastic bronchitis.<sup>
<xref ref-type="bibr" rid="bibr8-2150135112438107">8</xref>
</sup>
</p>
<p>Madsen et al<sup>
<xref ref-type="bibr" rid="bibr8-2150135112438107">8</xref>
</sup> propose acellular cast formation to be the result of mucous hypersecretion triggered by an inflammatory insult in genetically predisposed individuals. They suggest that the predisposing trait may be coinherited with CHD or unveiled by the inflammatory event, which might arise in the aftermath of cardiac surgery. This theory is intriguing as it adds a new level of complexity to the pathogenic equation, which could help to account for why plastic bronchitis is observed only rarely in Fontan patients. However, the theory does not describe a role for Fontan physiology in the pathogenesis of plastic bronchitis. Because the great majority of acellular plastic bronchitis cases occurs in patients with circulations representative of, or similar to, that created by the Fontan operation, this hypothesis may be incomplete.</p>
<p>
<italic>Protein-losing enteropathy as a pathophysiologic model. </italic>Inherent in this collection of theories is the implication that plastic bronchitis may have a pathological basis similar to that of PLE. A life-threatening disorder characterized by severe enteric protein loss, PLE is more common than plastic bronchitis within the Fontan population, with an estimated incidence as high as 13.4%.<sup>
<xref ref-type="bibr" rid="bibr20-2150135112438107">20</xref>
</sup> While its pathophysiology also remains to be definitively elucidated, PLE has been studied more extensively than plastic bronchitis, and knowledge of its etiology may provide insight into the mechanisms underlying bronchial cast formation.</p>
<p>The Fontan physiology is thought to play a key role in the development of Fontan-associated PLE. Low cardiac output necessitates the preferential perfusion of vital organ systems, potentially leading to an increase in mesenteric vascular resistance. It has been suggested that this may induce chronic, low-level ischemia in the intestinal mucosa resulting in diminished integrity of the epithelial barrier and loss of serum proteins into the gut.<sup>
<xref ref-type="bibr" rid="bibr21-2150135112438107">21</xref>
</sup> At the same time, elevated systemic venous pressure may obstruct intrathoracic lymphatic drainage, leading to dilation of intestinal lymphatics.<sup>
<xref ref-type="bibr" rid="bibr22-2150135112438107">22</xref>
</sup> This has led to the hypothesis that increased lymphatic fluid pressures may push fluid and proteins through the epithelial barrier and into the intestinal lumen.<sup>
<xref ref-type="bibr" rid="bibr22-2150135112438107">22</xref>
</sup>
</p>
<p>There is increasing evidence to suggest that genetic factors and environmental insults are central to PLE pathogenesis as well. Genetic predisposition may exist in patients with mutations affecting the expression of heparan sulfate (HS).<sup>
<xref ref-type="bibr" rid="bibr23-2150135112438107">23</xref>
</sup> A glycosaminoglycan ubiquitous in the body, HS binds reversibly to a myriad of cytokines, selectively enhancing or repressing their effects.<sup>
<xref ref-type="bibr" rid="bibr24-2150135112438107">24</xref>
</sup> Cell surface HS is found in greatest concentration at focal adhesions and cell contact areas, suggesting a role in the preservation of tissue integrity.<sup>
<xref ref-type="bibr" rid="bibr25-2150135112438107">25</xref>
</sup> Loss of HS from the basolateral surface of intestinal epithelial cells has been observed in patients with active PLE, with return of HS upon resolution of the enteropathy.<sup>
<xref ref-type="bibr" rid="bibr26-2150135112438107">26</xref>,<xref ref-type="bibr" rid="bibr27-2150135112438107">27</xref>
</sup> While the reason for this localized, temporal loss of HS remains unclear, it has been hypothesized that haploinsufficient mutations in genes affecting HS expression combined with the especially rapid turnover of epithelial cells during inflammation and infection may be responsible.<sup>
<xref ref-type="bibr" rid="bibr28-2150135112438107">28</xref>
</sup>
</p>
<p>Inflammation and infection are, in turn, likely environmental stimuli in the pathogenesis of PLE. The majority of Fontan patients who present with initial symptoms of PLE demonstrates elevated levels of interferon-γ (IFN-γ)<sup>
<xref ref-type="bibr" rid="bibr29-2150135112438107">29</xref>
</sup> and tumor necrosis factor-α (TNF-α),<sup>
<xref ref-type="bibr" rid="bibr30-2150135112438107">30</xref>
</sup> cytokines associated with viral infections and the proinflammatory state, respectively. These cytokines are known to disrupt tight junctions and contribute to paracellular protein leakage.<sup>
<xref ref-type="bibr" rid="bibr31-2150135112438107">31</xref>
<xref ref-type="bibr" rid="bibr32-2150135112438107"/>–<xref ref-type="bibr" rid="bibr33-2150135112438107">33</xref>
</sup> Under normal circumstances, it appears that HS binds to IFN-γ and TNF-α, reducing the availability and activity of these cytokines.<sup>
<xref ref-type="bibr" rid="bibr34-2150135112438107">34</xref>
</sup> Loss of HS in the mesenteric tissue may therefore enable IFN-γ and TNF-α to disrupt the intestinal epithelium to a greater extent.<sup>
<xref ref-type="bibr" rid="bibr34-2150135112438107">34</xref>
</sup>
</p>
<p>In a series of experiments using in vitro and mouse models, Bode et al<sup>
<xref ref-type="bibr" rid="bibr34-2150135112438107">34</xref>,<xref ref-type="bibr" rid="bibr35-2150135112438107">35</xref>
</sup> have shown that while IFN-γ, TNF-α, and loss of HS, as individual factors, have only minimal effects on the integrity of the intestinal epithelium, their combined presence produces notable damage. Moreover, these investigators have shown that when basolateral fluid pressure is elevated in the setting of IFN-γ, TNF-α, and HS loss, maximal disruption of the epithelium is observed, with a more than 25-fold increase in protein leakage. The elevation in fluid pressure, analogous to systemic venous hypertension, serves as a model for how the Fontan physiology may increase an individual’s risk of developing PLE in the event of intestinal inflammation and HS loss. These findings have led Bode et al to conclude that in the Fontan population, PLE is triggered by the combination of systemic venous hypertension, HS loss, viral infection, and inflammation.</p>
<p>
<italic>A multifactorial pathogenesis of post-Fontan plastic bronchitis</italic>. Given the theory of Bode et al, it seems plausible that plastic bronchitis in patients with Fontan physiology may have a similarly multifactorial pathogenesis. The possibility that mutations in HS genes might predispose to bronchial cast formation is intriguing, but has not been studied in this population. The most abundant sulfated glycosaminoglycan in the pulmonary parenchyma,<sup>
<xref ref-type="bibr" rid="bibr24-2150135112438107">24</xref>
</sup> HS is involved in many cellular processes within the lung, including cell proliferation and differentiation, cell adhesion, metastasis, angiogenesis, and tissue repair.<sup>
<xref ref-type="bibr" rid="bibr36-2150135112438107">36</xref>
</sup> Heparan sulfate has been shown to attenuate allergic lung inflammation in mice by relegating inflammation to specific sites of epithelial injury.<sup>
<xref ref-type="bibr" rid="bibr37-2150135112438107">37</xref>
</sup> Speculatively, its role as an inflammatory modulator may be such that reduced expression of HS exacerbates inflammatory damage to the pulmonary epithelium. It is interesting to note that not only is loss of HS in the intestinal mucosa associated with PLE,<sup>
<xref ref-type="bibr" rid="bibr26-2150135112438107">26</xref>,<xref ref-type="bibr" rid="bibr27-2150135112438107">27</xref>
</sup> but the loss of HS in the renal glomeruli has been implicated in proteinuria.<sup>
<xref ref-type="bibr" rid="bibr38-2150135112438107">38</xref>
</sup> That reduced HS appears to be a factor in protein-losing conditions in multiple organ systems implies that its loss from pulmonary epithelial cells may have a similar effect. Inflammation is also a likely trigger. Tumor necrosis factor-α has been shown to disrupt tight junctions in the lungs of mouse models during the inflammatory state, suggesting a role in pulmonary epithelial barrier dysfunction.<sup>
<xref ref-type="bibr" rid="bibr39-2150135112438107">39</xref>
</sup> Were pulmonary inflammation and HS loss to arise in a patient with Fontan physiology and impose damage on the respiratory epithelium, the pressure threshold necessary for lymphatic fluid to leak into the endobronchial space could be reduced. Chyle leakage and proinflammatory cytokines might then stimulate varying degrees of mucous hypersecretion, allowing for casts that are especially chylous in some cases and those that are mainly mucinous in others. In this way, bronchial casts might arise from the confluence of genetic makeup, inflammation, and the Fontan physiology.</p>
<p>The natural histories of plastic bronchitis in our two patients seem compatible with this theory. The resolution of symptoms experienced by the first patient in the six months following Fontan conversion with AV valve replacement suggests that improved hemodynamics is of therapeutic benefit. When the patient’s plastic bronchitis recurred as a chronic condition, his Fontan pathway pressures were found to once again be elevated despite the conversion surgery, potentially reestablishing the foundation on which an inflammatory insult might trigger bronchial cast formation. Genetic factors and environmental stimuli also appear to have potential roles in this patient’s disease. Both prior to and after Fontan conversion surgery, the patient’s symptoms followed a generally predictable course, with aggravation during the fall and winter months and alleviation in the spring and summer. This cycle is consistent with that of his sibling’s allergies, suggesting the possibility of a latent allergy in our patient with the potential to trigger low-grade pulmonary inflammation in response to some seasonal stimulus. That the patient’s casts contain inflammatory cells further indicates an inflammatory trigger. Although the presence of inflammatory cells in casts associated with palliated CHD is uncommon, lack of inflammatory cells in bronchial casts does not preclude bronchopulmonary inflammation.<sup>
<xref ref-type="bibr" rid="bibr8-2150135112438107">8</xref>
</sup> Therefore, while our patient’s disease course could be an exception to the norm, it could also be a more overt manifestation of a common pathophysiological process.</p>
<p>The second patient’s course was notable for recurrent issues with chylous pleural effusions after each of her cardiac surgeries. These had resolved, however, well before her Fontan completion, and her preoperative cardiac hemodynamics did not raise any concerns for proceeding to Fontan. One possible trigger for her development of plastic bronchitis could have been her chemical pleurodesis. While this did not entirely resolve her pleural effusions, it is plausible that this may have led to an increase in the resistance to efflux of her lymphatic fluid into the pleural space, as well as having been a proinflammatory trigger. If the lymphatic production increased or remained stable, but was less able to efflux into the pleural space, this may have led to an increase in the pressure driving lymph across her respiratory bed and into her lungs and eventually into the airways. Interestingly, simply reverting to her preoperative anatomy did not reverse her plastic bronchitis. This would argue that it cannot simply be the Fontan physiology alone that leads to the ongoing propagation of cast formation in plastic bronchitis.</p>
</sec>
</sec>
<sec id="section8-2150135112438107">
<title>Treatment</title>
<p>A multifactorial pathogenesis of plastic bronchitis in patients with Fontan physiology would likely require a multifactorial treatment strategy. Several medical and surgical therapies have been described in isolated case reports to date, including mucolytics,<sup>
<xref ref-type="bibr" rid="bibr10-2150135112438107">10</xref>
</sup> bronchodilators,<sup>
<xref ref-type="bibr" rid="bibr10-2150135112438107">10</xref>
</sup> urokinase,<sup>
<xref ref-type="bibr" rid="bibr10-2150135112438107">10</xref>
</sup> tissue plasminogen activator,<sup>
<xref ref-type="bibr" rid="bibr40-2150135112438107">40</xref>
</sup> bosentan,<sup>
<xref ref-type="bibr" rid="bibr16-2150135112438107">16</xref>
</sup> sildenafil,<sup>
<xref ref-type="bibr" rid="bibr41-2150135112438107">41</xref>
</sup> heparin,<sup>
<xref ref-type="bibr" rid="bibr42-2150135112438107">42</xref>
</sup> corticosteroids,<sup>
<xref ref-type="bibr" rid="bibr43-2150135112438107">43</xref>
</sup> atrial pacing,<sup>
<xref ref-type="bibr" rid="bibr14-2150135112438107">14</xref>
</sup> fenestration of the Fontan circuit,<sup>
<xref ref-type="bibr" rid="bibr11-2150135112438107">11</xref>
</sup> thoracic duct ligation,<sup>
<xref ref-type="bibr" rid="bibr18-2150135112438107">18</xref>
</sup> Fontan conversion,<sup>
<xref ref-type="bibr" rid="bibr44-2150135112438107">44</xref>
</sup> and cardiac transplantation.<sup>
<xref ref-type="bibr" rid="bibr45-2150135112438107">45</xref>,<xref ref-type="bibr" rid="bibr46-2150135112438107">46</xref>
</sup> While the success of many of these therapies has been variable and limited to small numbers of patients, it is intriguing that several have also demonstrated empiric success in the treatment of PLE. Potential similarities in the therapeutic mechanisms effective in treating these two conditions further speaks to the possibility of a similar pathophysiology and may help to identify therapies that would be of benefit in a comprehensive treatment strategy for plastic bronchitis.</p>
<p>
<italic>Medical therapies</italic>. High-molecular-weight (HMW) heparin is one therapy that has shown promise in the treatment of both PLE and plastic bronchitis. Several case reports have described a correlation between the administration of HMW heparin and the rapid resolution of PLE symptoms.<sup>
<xref ref-type="bibr" rid="bibr25-2150135112438107">25</xref>,<xref ref-type="bibr" rid="bibr47-2150135112438107">47</xref>
</sup> In addition, treatment with HMW heparin was associated with complete cessation of plastic bronchitis symptoms in one patient, with a severe relapse occurring on discontinuation of the drug and subsequent resolution upon its readministration.<sup>
<xref ref-type="bibr" rid="bibr42-2150135112438107">42</xref>
</sup> While the mechanism by which heparin may alleviate PLE and plastic bronchitis is unknown, it is possible that heparin substitutes for lost endogenous HS.<sup>
<xref ref-type="bibr" rid="bibr35-2150135112438107">35</xref>
</sup> Like HS, heparin inactivates both IFN-γ and TNF-α,<sup>
<xref ref-type="bibr" rid="bibr48-2150135112438107">48</xref>
<xref ref-type="bibr" rid="bibr49-2150135112438107"/>–<xref ref-type="bibr" rid="bibr50-2150135112438107">50</xref>
</sup> potentially minimizing the damaging effects of these cytokines. Bode et al have demonstrated that heparin prevents cytokine-induced protein leakage across the intestinal epithelial layer in vitro and in mice.<sup>
<xref ref-type="bibr" rid="bibr35-2150135112438107">35</xref>
</sup> Additionally, these investigators have shown a nonanticoagulant heparin derivative to have a comparable efficacy, suggesting the possibility of a similar treatment without the severe side effects of HMW heparin.<sup>
<xref ref-type="bibr" rid="bibr35-2150135112438107">35</xref>
</sup>
</p>
<p>Corticosteroids have also demonstrated some success.<sup>
<xref ref-type="bibr" rid="bibr43-2150135112438107">43</xref>,<xref ref-type="bibr" rid="bibr51-2150135112438107">51</xref>,<xref ref-type="bibr" rid="bibr52-2150135112438107">52</xref>
</sup> A small number of case reports have described PLE resolution with intravenous or oral prednisone, with recurrences when treatment was stopped and improvement upon readministration of the drug.<sup>
<xref ref-type="bibr" rid="bibr51-2150135112438107">51</xref>,<xref ref-type="bibr" rid="bibr52-2150135112438107">52</xref>
</sup> Administration of oral prednisone was also shown to correspond with the resolution of plastic bronchitis symptoms in one patient with primarily acellular casts,<sup>
<xref ref-type="bibr" rid="bibr43-2150135112438107">43</xref>
</sup> although it was not successful in our second patient. The antiinflammatory properties of corticosteroids are thought to be responsible for their reported therapeutic effects,<sup>
<xref ref-type="bibr" rid="bibr43-2150135112438107">43</xref>,<xref ref-type="bibr" rid="bibr51-2150135112438107">51</xref>
</sup> though this mechanism has yet to be confirmed. While the side effects of corticosteroids may be prohibitive, recent reports<sup>
<xref ref-type="bibr" rid="bibr53-2150135112438107">53</xref>,<xref ref-type="bibr" rid="bibr54-2150135112438107">54</xref>
</sup> describing the successful use of oral budesonide in the treatment of PLE suggest that perhaps topical airway steroids would provide a safe therapeutic alternative in patients with plastic bronchitis.</p>
<p>Importantly, the empiric success of HMW heparin and corticosteroids in the treatment of PLE and plastic bronchitis is matched by reports of these therapies proving to be of little benefit,<sup>
<xref ref-type="bibr" rid="bibr55-2150135112438107">55</xref>,<xref ref-type="bibr" rid="bibr56-2150135112438107">56</xref>
</sup> as in our patient. High-molecular-weight heparin and corticosteroids may address specific factors that contribute to the development of these conditions, but it is unlikely that either is generally effective in resolving PLE or plastic bronchitis on its own. Further investigation into the mechanisms and efficacies of these drugs is therefore needed.</p>
<p>
<italic>Atrial pacing, Fontan fenestration, and thoracic duct ligation. </italic>Transcatheter and surgical strategies that have been used in attempts to normalize hemodynamics in PLE and plastic bronchitis patients include atrial pacing, fenestration of the Fontan circuit, thoracic duct ligation or diversion, Fontan conversion, and cardiac transplantation. Atrial pacing as a means of improving cardiac output in Fontan patients with arrhythmias has reportedly corresponded with the resolution of PLE<sup>
<xref ref-type="bibr" rid="bibr57-2150135112438107">57</xref>
</sup> and plastic bronchitis<sup>
<xref ref-type="bibr" rid="bibr14-2150135112438107">14</xref>
</sup> symptoms, though such reports are so rare that much additional investigation is required to better understand the potential therapeutic role of this intervention.</p>
<p>Fontan fenestration as a means of reducing systemic venous pressures and improving cardiac output has been tried with variable success, with results ranging from little change in symptoms<sup>
<xref ref-type="bibr" rid="bibr16-2150135112438107">16</xref>,<xref ref-type="bibr" rid="bibr17-2150135112438107">17</xref>,<xref ref-type="bibr" rid="bibr58-2150135112438107">58</xref>
</sup> to their complete resolution.<sup>
<xref ref-type="bibr" rid="bibr11-2150135112438107">11</xref>
<xref ref-type="bibr" rid="bibr12-2150135112438107"/>–<xref ref-type="bibr" rid="bibr13-2150135112438107">13</xref>,<xref ref-type="bibr" rid="bibr58-2150135112438107">58</xref>
</sup> In general, it appears that Fontan fenestration may lead to some symptomatic relief though, as a singular approach, it is likely inadequate for the treatment of these pathologies.<sup>
<xref ref-type="bibr" rid="bibr55-2150135112438107">55</xref>,<xref ref-type="bibr" rid="bibr58-2150135112438107">58</xref>
</sup> The high probability of spontaneous closure of catheter-created fenestrations has made this a frustrating therapeutic strategy, at times. The use of surgically created fenestrations, which may be more reliable than those created during an interventional catheter procedure, could produce more consistent, long-lasting effects.<sup>
<xref ref-type="bibr" rid="bibr59-2150135112438107">59</xref>,<xref ref-type="bibr" rid="bibr60-2150135112438107">60</xref>
</sup>
</p>
<p>Diversion or ligation of the thoracic duct as a means of alleviating a congested lymphatic system has also been described to a limited extent.<sup>
<xref ref-type="bibr" rid="bibr18-2150135112438107">18</xref>,<xref ref-type="bibr" rid="bibr19-2150135112438107">19</xref>,<xref ref-type="bibr" rid="bibr56-2150135112438107">56</xref>
</sup> In one institutional review, it was noted that the only surgical intervention besides cardiac transplantation to result in lasting resolution of PLE was diversion of an obstructed thoracic duct to an alternate systemic vein.<sup>
<xref ref-type="bibr" rid="bibr56-2150135112438107">56</xref>
</sup> Additionally, thoracic duct ligation was shown to correspond with the complete resolution of acellular plastic bronchitis in two patients,<sup>
<xref ref-type="bibr" rid="bibr18-2150135112438107">18</xref>
</sup> though the procedure demonstrated no effect when attempted in a Fontan patient with inflammatory casts.<sup>
<xref ref-type="bibr" rid="bibr19-2150135112438107">19</xref>
</sup> This intervention may carry some promise, particularly if lymphatic leakage does in fact contribute to PLE and bronchial cast formation, though like the other therapies described its clinical use requires further study.</p>
<p>
<italic>Fontan conversion and cardiac transplantation</italic>. Fontan conversion and cardiac transplantation represent final therapeutic options for patients with failed Fontan physiology complicated by PLE or plastic bronchitis. These therapies tend to carry considerable operative risk, given the surgical history, comorbidities, and generally poor hemodynamics of most patients at the time of operation. However, for some, cardiac surgery in the form of one of these procedures may be the only option.</p>
<p>Conversion of the Fontan circuit from a less hemodynamically favorable state to one with better blood flow and pressures may be considered in certain patients with failing Fontan physiology. The procedure typically involves conversion of an atriopulmonary connection (or, less often, a hemodynamically unstable lateral tunnel anastomosis) to a total cavopulmonary extracardiac or lateral tunnel connection. The intended effect is a reduction in systemic venous pressures, improved cardiac output, and alleviation of any consequent symptoms. Fontan conversion is often used in conjunction with arrhythmia surgery in patients with refractory atrial arrhythmias. In these patients, low postoperative mortality and promising short- and mid-term arrhythmia control has been observed.<sup>
<xref ref-type="bibr" rid="bibr61-2150135112438107">61</xref>
</sup> Evidence as to the use and effectiveness of Fontan conversion in patients with PLE or plastic bronchitis, however, is limited.</p>
<p>A small number of case reports have described the complete resolution of PLE after conversion to a more hemodynamically stable Fontan circuit,<sup>
<xref ref-type="bibr" rid="bibr62-2150135112438107">62</xref>,<xref ref-type="bibr" rid="bibr63-2150135112438107">63</xref>
</sup> though the outcomes are variable, and PLE is considered by some to be an incremental risk factor for mortality associated with Fontan conversion. One multi-institutional, retrospective analysis, for instance, found that of 13 Fontan patients with PLE who underwent Fontan conversion, 6 died, 4 continued to experience active PLE, and 3 demonstrated apparent resolution of symptoms.<sup>
<xref ref-type="bibr" rid="bibr55-2150135112438107">55</xref>
</sup>
</p>
<p>To our knowledge, there is only one published report of Fontan conversion attempted as treatment for plastic bronchitis, apart from the case described here. In that report,<sup>
<xref ref-type="bibr" rid="bibr44-2150135112438107">44</xref>
</sup> an atriopulmonary to total cavopulmonary extracardiac conversion failed to resolve the symptoms of plastic bronchitis, with extensive bronchial cast production occurring in the postoperative period and persisting until the administration of aerosolized urokinase. In our patient, conversion from a lateral tunnel to total extracardiac conduit with simultaneous AV valve replacement demonstrated promising short-term results, though seven months after the operation the patient experienced a recurrence of symptoms that have only grown worse with time. Fontan conversion has therefore been ineffective in the treatment of plastic bronchitis in two reported instances. Whether it has the potential to be of benefit in some patients is unknown.</p>
<p>Cardiac transplantation may provide definitive palliation to the Fontan patient through the restoration of a two-ventricle circulation and, ideally, normal hemodynamics. However, the demand for donor hearts exceeds the supply, and for the recipient, transplantation comes at the cost of life-long immunosuppression and the possibility of chronic rejection. It has been argued that failing Fontan patients constitute one of the highest risk heart transplant groups.<sup>
<xref ref-type="bibr" rid="bibr64-2150135112438107">64</xref>
</sup> Yet, recent studies have indicated that results of cardiac transplantation in Fontan patients are similar to those of patients without CHD,<sup>
<xref ref-type="bibr" rid="bibr65-2150135112438107">65</xref>
<xref ref-type="bibr" rid="bibr66-2150135112438107"/>–<xref ref-type="bibr" rid="bibr67-2150135112438107">67</xref>
</sup> with one multicenter investigation finding slightly higher posttransplantation mortality in the Fontan group but similar survival rates in Fontan and non-CHD patients one year after transplant.<sup>
<xref ref-type="bibr" rid="bibr66-2150135112438107">66</xref>
</sup>
</p>
<p>Cardiac transplantation as treatment for Fontan-associated PLE has demonstrated much initial success, with several reports describing the complete resolution of PLE after transplantation.<sup>
<xref ref-type="bibr" rid="bibr65-2150135112438107">65</xref>
<xref ref-type="bibr" rid="bibr66-2150135112438107"/>
<xref ref-type="bibr" rid="bibr67-2150135112438107"/>
<xref ref-type="bibr" rid="bibr68-2150135112438107"/>–<xref ref-type="bibr" rid="bibr69-2150135112438107">69</xref>
</sup> In addition, one retrospective, multi-institutional review performed in Fontan patients listed for heart transplant found that of those with preexisting PLE who survived more than 30 days postoperatively (n = 19), 100% experienced total resolution of PLE symptoms.<sup>
<xref ref-type="bibr" rid="bibr66-2150135112438107">66</xref>
</sup> This study also found no increased risk of death, before or after transplantation, in patients with PLE as compared to other Fontan patients listed for transplant. Instances of PLE recalcitrant to transplantation have also been reported<sup>
<xref ref-type="bibr" rid="bibr55-2150135112438107">55</xref>
</sup> though to a lesser extent. The reasons for PLE resolution in many instances of cardiac transplantation but not all are unclear and merit further investigation.</p>
<p>The effectiveness of cardiac transplantation in the treatment of Fontan-associated plastic bronchitis has, to our knowledge, only been described in two recent case reports<sup>
<xref ref-type="bibr" rid="bibr45-2150135112438107">45</xref>,<xref ref-type="bibr" rid="bibr46-2150135112438107">46</xref>
</sup> apart from the case presented here. In each instance, the failure of medical management to improve cast production led to the decision to list the patient for transplant, and the operation was followed by resolution of plastic bronchitis symptoms. Follow-up interval for these patients has been short, with only three months and one year posttransplant data available, respectively. Our patient, who was forming casts every 1 to 2 weeks pretransplantation, is now over 18 months cast free. The mechanism for this durable response is not clear, but the presence of a ventricular pump providing pulsatile flow to the pulmonary bed could be postulated to improve the forward flow through the pulmonary vasculature.</p>
<p>It is conceivable that additional surgical strategies which specifically address the hemodynamics of the Fontan circulation (such as mechanical circulatory support) may be of some benefit in alleviating plastic bronchitis. To our knowledge, mechanical circulatory support as a bridge to transplantation in the setting of plastic bronchitis has not been performed but is an intriguing possibility. Opportunities for takedown of the Fontan connection with conversion to biventricular circulation are extremely rare and should be carefully weighed against the current outcomes of cardiac transplantation.</p>
<p>For Fontan patients facing the high morbidity and mortality associated with plastic bronchitis, the improvement in hemodynamics attained through Fontan conversion or cardiac transplantation may have the potential to alleviate or completely resolve bronchial cast formation. Though our results are limited to just two case studies, we speculate that Fontan conversion may not result consistently in sustained resolution of plastic bronchitis, while cardiac transplantation appears more promising. Conversion to a total cavopulmonary connection improves hemodynamics in the short term, but leaves the patient with a Fontan circuit that remains susceptible to reduced flow and increased pressures over time. Although transplantation comes with several risks of its own, these may be outweighed by the lasting improvement in hemodynamics and, potentially, lasting resolution of bronchial cast production.</p>
</sec>
</sec>
<sec id="section9-2150135112438107">
<title>Conclusion</title>
<p>Plastic bronchitis is a rare, life-threatening condition that may arise in patients with functionally univentricular hearts palliated with a Fontan operation. While its pathophysiology is incompletely understood, intriguing similarities exist between this condition and PLE, which may help to elucidate our understanding of bronchial cast formation. Specifically, genetic factors, inflammation, and elevated systemic venous pressures may each contribute to the pathogenesis of plastic bronchitis. Treatment remains a challenge, and no strategies have been proven consistently effective. Medical and surgical therapies that target predisposing genetic insufficiencies, bronchopulmonary inflammation, and poor hemodynamics may be of value, though further investigation is needed. The experience that we describe in this report suggests that Fontan conversion may not be adequate therapy for patients with plastic bronchitis, while cardiac transplantation seems promising and merits further investigation. Given the small number of patients with plastic bronchitis seen at any given center, a multicenter investigation to study the effects of cardiac transplantation on the outcomes of plastic bronchitis would be of value for this small but vulnerable patient population.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors thank Allison Siegel for her many contributions to the preparation of this article.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-2150135112438107">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-2150135112438107">
<label>Funding</label>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: a stipend from the Research Training in Heart, Lung, Blood, and Sleep Diseases Training Grant T35 HL082544 to Madeleine LaRue.</p>
</fn>
</fn-group>
<glossary content-type="abbr">
<title>Abbreviations and Acronyms</title>
<def-list>
<def-item>
<term id="term1-2150135112438107">AV</term>
<def>
<p>atrioventricular</p>
</def>
</def-item>
<def-item>
<term id="term2-2150135112438107">CHD</term>
<def>
<p>congenital heart disease</p>
</def>
</def-item>
<def-item>
<term id="term3-2150135112438107">HMW</term>
<def>
<p>high molecular weight</p>
</def>
</def-item>
<def-item>
<term id="term4-2150135112438107">HS</term>
<def>
<p>heparan sulfate</p>
</def>
</def-item>
<def-item>
<term id="term5-2150135112438107">IFN-γ</term>
<def>
<p>interferon-γ</p>
</def>
</def-item>
<def-item>
<term id="term6-2150135112438107">PLE</term>
<def>
<p>protein-losing enteropathy</p>
</def>
</def-item>
<def-item>
<term id="term7-2150135112438107">TNF-α</term>
<def>
<p>tumor necrosis factor-α</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="bibr1-2150135112438107">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobs</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Pelletier</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Late complications associated with the Fontan circulation</article-title>. <source>Cardiol Young</source>. <year>2006</year>;<volume>16</volume>(<issue>suppl 1</issue>):<fpage>80</fpage>-<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr2-2150135112438107">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trojnarska</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Cieplucha</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Challenges of management and therapy in patients with a functionally single ventricle after the Fontan operation</article-title>. <source>Cardiol J</source>. <year>2011</year>;<volume>18</volume>(<issue>2</issue>):<fpage>119</fpage>-<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr3-2150135112438107">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beghetti</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Fontan and the pulmonary circulation: a potential role for new hypertension therapies</article-title>. <source>Heart</source>. <year>2010</year>;<volume>96</volume>(<issue>12</issue>):<fpage>911</fpage>-<lpage>916</lpage>.</citation>
</ref>
<ref id="bibr4-2150135112438107">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seear</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Magee</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bohn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cutz</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Bronchial casts in children: a proposed classification based on nine cases and a review of the literature</article-title>. <source>Am J Respir Crit Care Med</source>. <year>1997</year>;<volume>155</volume>(<issue>1</issue>):<fpage>364</fpage>-<lpage>370</lpage>.</citation>
</ref>
<ref id="bibr5-2150135112438107">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Do</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Berdjis</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Anas</surname>
<given-names>NG</given-names>
</name>
</person-group>. <article-title>Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature</article-title>. <source>Pediatr Cardiol</source>. <year>2009</year>;<volume>30</volume>(<issue>3</issue>):<fpage>352</fpage>-<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr6-2150135112438107">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brogan</surname>
<given-names>TV</given-names>
</name>
<name>
<surname>Finn</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Pyskaty</surname>
<given-names>DJ</given-names>
</name>
<etal/>
</person-group> <article-title>Plastic bronchitis in children: a case series and review of the medical literature</article-title>. <source>Pediatr Pulmonol</source>. <year>2002</year>;<volume>34</volume>(<issue>6</issue>):<fpage>482</fpage>-<lpage>487</lpage>.</citation>
</ref>
<ref id="bibr7-2150135112438107">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Book</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Conley</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Kerschner</surname>
<given-names>JE</given-names>
</name>
</person-group>. <article-title>Plastic bronchitis: an unusual bronchoscopic challenge associated with congenital heart disease repair</article-title>. <source>Int J Pediatr Otorhinolaryngol</source>. <year>2003</year>;<volume>67</volume>(<issue>5</issue>):<fpage>543</fpage>-<lpage>548</lpage>.</citation>
</ref>
<ref id="bibr8-2150135112438107">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madsen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Rubin</surname>
<given-names>BK</given-names>
</name>
</person-group>. <article-title>Plastic bronchitis: new insights and a classification scheme</article-title>. <source>Paediatr Respir Rev</source>. <year>2005</year>;<volume>6</volume>(<issue>4</issue>):<fpage>292</fpage>-<lpage>300</lpage>.</citation>
</ref>
<ref id="bibr9-2150135112438107">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Languepin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Scheinmann</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mahut</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>Bronchial casts in children with cardiomyopathies: the role of pulmonary lymphatic abnormalities</article-title>. <source>Pediatr Pulmonol</source>. <year>1999</year>;<volume>28</volume>(<issue>5</issue>):<fpage>329</fpage>-<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr10-2150135112438107">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Quasney</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Orman</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group> <article-title>Plastic bronchitis occurring late after the Fontan procedure: treatment with aerosolized urokinase</article-title>. <source>Crit Care Med</source>. <year>2000</year>;<volume>28</volume>(<issue>6</issue>):<fpage>2107</fpage>-<lpage>2111</lpage>.</citation>
</ref>
<ref id="bibr11-2150135112438107">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaudhari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Stumper</surname>
<given-names>O</given-names>
</name>
</person-group>. <article-title>Plastic bronchitis after Fontan operation: treatment with stent fenestration of the Fontan circuit</article-title>. <source>Heart</source>. <year>2004</year>;<volume>90</volume>(<issue>7</issue>):<fpage>801</fpage>.</citation>
</ref>
<ref id="bibr12-2150135112438107">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Benson</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Fenestration of the Fontan circuit as treatment for plastic bronchitis</article-title>. <source>Pediatr Cardiol</source>. <year>2005</year>;<volume>26</volume>(<issue>5</issue>):<fpage>717</fpage>-<lpage>719</lpage>.</citation>
</ref>
<ref id="bibr13-2150135112438107">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yalcin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ozcelik</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Celiker</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Plastic bronchitis occurring late after the Fontan procedure in a child: treatment with stent implantation in the left pulmonary artery</article-title>. <source>J Invasive Cardiol</source>. <year>2005</year>;<volume>17</volume>(<issue>6</issue>):<fpage>326</fpage>-<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr14-2150135112438107">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barber</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Burch</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Tripple</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Balaji</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Resolution of plastic bronchitis with atrial pacing in a patient with Fontan physiology</article-title>. <source>Pediatr Cardiol</source>. <year>2004</year>;<volume>25</volume>(<issue>1</issue>):<fpage>73</fpage>-<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr15-2150135112438107">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goo</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Jhang</surname>
<given-names>WK</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YH</given-names>
</name>
<etal/>
</person-group> <article-title>CT findings of plastic bronchitis in children after a Fontan operation</article-title>. <source>Pediatr Radiol</source>. <year>2008</year>;<volume>38</volume>(<issue>9</issue>):<fpage>989</fpage>-<lpage>993</lpage>.</citation>
</ref>
<ref id="bibr16-2150135112438107">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apostolopoulou</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Papagiannis</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rammos</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation</article-title>. <source>J Heart Lung Transplant</source>. <year>2005</year>;<volume>24</volume>(<issue>8</issue>):<fpage>1174</fpage>-<lpage>1176</lpage>.</citation>
</ref>
<ref id="bibr17-2150135112438107">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMahon</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Nihill</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Reber</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>The bronchial cast syndrome after the Fontan procedure: further evidence of its etiology</article-title>. <source>Cardiol Young</source>. <year>2001</year>;<volume>11</volume>(<issue>3</issue>):<fpage>345</fpage>-<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr18-2150135112438107">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>SSA</given-names>
</name>
<name>
<surname>Drinkwater</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Christian</surname>
<given-names>KG</given-names>
</name>
</person-group>. <article-title>Plastic bronchitis: is thoracic duct ligation a real surgical option?</article-title> <source>Ann Thorac Surg</source>. <year>2006</year>;<volume>81</volume>(<issue>6</issue>):<fpage>2281</fpage>-<lpage>2283</lpage>.</citation>
</ref>
<ref id="bibr19-2150135112438107">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nayar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Parmar</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cherian</surname>
<given-names>KM</given-names>
</name>
</person-group>. <article-title>Treatment of plastic bronchitis</article-title>. <source>Ann Thorac Surg</source>. <year>2007</year>;<volume>83</volume>(<issue>5</issue>):<fpage>1884</fpage>-<lpage>1886</lpage>.</citation>
</ref>
<ref id="bibr20-2150135112438107">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldt</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Driscoll</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Offord</surname>
<given-names>KP</given-names>
</name>
<etal/>
</person-group> <article-title>Protein-losing enteropathy after the Fontan operation</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>1996</year>;<volume>112</volume>(<issue>3</issue>):<fpage>672</fpage>-<lpage>680</lpage>.</citation>
</ref>
<ref id="bibr21-2150135112438107">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldberg</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Dodds</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Rychik</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Rare problems associated with the Fontan circulation</article-title>. <source>Cardiol Young</source>. <year>2010</year>;<volume>20</volume>(<issue>suppl 3</issue>):<fpage>113</fpage>-<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr22-2150135112438107">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hess</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kruizinga</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bijleveld</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Hardjowijono</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Eygelaar</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Protein-losing enteropathy after Fontan operation</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>1984</year>;<volume>88</volume>(<issue>4</issue>):<fpage>606</fpage>-<lpage>609</lpage>.</citation>
</ref>
<ref id="bibr23-2150135112438107">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murch</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Winyard</surname>
<given-names>PJD</given-names>
</name>
<name>
<surname>Koletzko</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Congenital enterocyte heparan sulfate deficiency with massive albumin loss, secretory diarrhea, and malnutrition</article-title>. <source>Lancet</source>. <year>1996</year>;<volume>347</volume>(<issue>9011</issue>):<fpage>1299</fpage>-<lpage>1301</lpage>.</citation>
</ref>
<ref id="bibr24-2150135112438107">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papakonstantinou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Karakiulakis</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>The sweet and bitter involvement of glycosaminoglycans in lung diseases: pharmacotherapeutic relevance</article-title>. <source>Br J Pharmacol</source>. <year>2009</year>;<volume>157</volume>(<issue>7</issue>):<fpage>1111</fpage>-<lpage>1127</lpage>.</citation>
</ref>
<ref id="bibr25-2150135112438107">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Donnelly</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Rosenthal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Castle</surname>
<given-names>VP</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>RD</given-names>
</name>
</person-group>. <article-title>Reversal of protein-losing enteropathy with heparin therapy in three patients with univentricular hearts and Fontan palliation</article-title>. <source>J Pediatr</source>. <year>1997</year>;<volume>130</volume>(<issue>3</issue>):<fpage>474</fpage>-<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr26-2150135112438107">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westphal</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Murch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation</article-title>. <source>Am J Pathol</source>. <year>2000</year>;<volume>157</volume>(<issue>6</issue>):<fpage>1917</fpage>-<lpage>1925</lpage>.</citation>
</ref>
<ref id="bibr27-2150135112438107">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Salvestrini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Myrdal</surname>
<given-names>U</given-names>
</name>
<etal/>
</person-group> <article-title>Focal loss of duodenal enterocyte heparan sulfate proteoglycans may contribute to protein-losing enteropathy after Fontan surgery. World Congress of Pediatric Gastroenterology, Hepatology and Nutrition: Paris, France</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2004</year>;<volume>39</volume>:<fpage>S278</fpage>-<lpage>S279</lpage>.</citation>
</ref>
<ref id="bibr28-2150135112438107">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hambsch</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection?</article-title> <source>Crit Care</source>. <year>2003</year>;<volume>7</volume>(<issue>2</issue>):<fpage>185</fpage>-<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr29-2150135112438107">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shimizu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fujii</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>Enhanced production of interferon-gamma as a possible cause of protein-losing enteropathy after modified Fontan operation</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2003</year>;<volume>37</volume>(<issue>4</issue>):<fpage>504</fpage>-<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr30-2150135112438107">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ostrow</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Freeze</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rychik</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms</article-title>. <source>Ann Thorac Surg</source>. <year>2006</year>;<volume>82</volume>(<issue>2</issue>):<fpage>695</fpage>-<lpage>700</lpage>.</citation>
</ref>
<ref id="bibr31-2150135112438107">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fromm</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bentzel</surname>
<given-names>CJ</given-names>
</name>
<etal/>
</person-group> <article-title>Tumor necrosis factor alpha regulates the epithelial barrier in the human intestinal cell line HT-29/B6</article-title>. <source>J Cell Sci</source>. <year>1999</year>;<volume>112</volume>(<issue>pt 1</issue>):<fpage>137</fpage>-<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr32-2150135112438107">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madara</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Stafford</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers</article-title>. <source>J Clin Invest</source>. <year>1989</year>;<volume>83</volume>(<issue>2</issue>):<fpage>724</fpage>-<lpage>727</lpage>.</citation>
</ref>
<ref id="bibr33-2150135112438107">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fish</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Proujansky</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Reenstra</surname>
<given-names>WW</given-names>
</name>
</person-group>. <article-title>Synergistic effects of interferon gamma and tumor necrosis factor alpha on T84 cell function</article-title>. <source>Gut</source>. <year>1999</year>;<volume>45</volume>(<issue>4</issue>):<fpage>191</fpage>-<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr34-2150135112438107">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bode</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Murch</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Freeze</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy</article-title>. <source>J Biol Chem</source>. <year>2006</year>;<volume>281</volume>(<issue>12</issue>):<fpage>7809</fpage>-<lpage>7815</lpage>.</citation>
</ref>
<ref id="bibr35-2150135112438107">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bode</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Salvestrini</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>PW</given-names>
</name>
<etal/>
</person-group> <article-title>Haparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function</article-title>. <source>J Clin Invest</source>. <year>2008</year>;<volume>118</volume>(<issue>1</issue>):<fpage>229</fpage>-<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr36-2150135112438107">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smits</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Shworak</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Dekhuijzen</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>van Kuppevelt</surname>
<given-names>TH</given-names>
</name>
</person-group>. <article-title>Heparan sulfates in the lung: structure, diversity, and role in pulmonary emphysema</article-title>. <source>Anat Rec (Hoboken)</source>. <year>2010</year>;<volume>293</volume>(<issue>6</issue>):<fpage>955</fpage>-<lpage>967</lpage>.</citation>
</ref>
<ref id="bibr37-2150135112438107">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Kheradmand</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Corry</surname>
<given-names>DB</given-names>
</name>
</person-group>. <article-title>Endogenous attenuation of allergic lung inflammation by syndecan-1</article-title>. <source>J Immunol</source>. <year>2005</year>;<volume>174</volume>(<issue>9</issue>):<fpage>5758</fpage>-<lpage>5765</lpage>.</citation>
</ref>
<ref id="bibr38-2150135112438107">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanwar</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Linker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Farquhar</surname>
<given-names>MG</given-names>
</name>
</person-group>. <article-title>Increased permeability of the glomerular basement membrane to ferritin after removal of glycosaminoglycans (heparan sulfate) by enzyme digestion</article-title>. <source>J Cell Biol</source>. <year>1980</year>;<volume>86</volume>(<issue>2</issue>):<fpage>688</fpage>-<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr39-2150135112438107">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazzon</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cuzzocrea</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Role of TNF-alpha in lung tight junction alteration in mouse model of acute lung inflammation</article-title>. <source>Respir Res</source>. <year>2007</year>;<volume>8</volume>:<fpage>75</fpage>.</citation>
</ref>
<ref id="bibr40-2150135112438107">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costello</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Steinhorn</surname>
<given-names>D</given-names>
</name>
<name>
<surname>McColley</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gerber</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>SP</given-names>
</name>
</person-group>. <article-title>Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature</article-title>. <source>Pediatrics</source>. <year>2002</year>;<volume>109</volume>(<issue>4</issue>):<fpage>e67</fpage>.</citation>
</ref>
<ref id="bibr41-2150135112438107">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haseyama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Satomi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yasukochi</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group> <article-title>Pulmonary vasodilation therapy with sildenafil citrate in a patient with plastic bronchitis after the Fontan procedure for hypoplastic left heart syndrome</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2006</year>;<volume>132</volume>(<issue>5</issue>):<fpage>1232</fpage>-<lpage>1233</lpage>.</citation>
</ref>
<ref id="bibr42-2150135112438107">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stiller</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Riedel</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>K</given-names>
</name>
<name>
<surname>van Landeghem</surname>
<given-names>FKH</given-names>
</name>
</person-group>. <article-title>Plastic bronchitis in children with Fontan palliation: analogue to protein-losing enteropathy?</article-title> <source>Pediatr Cardiol</source>. <year>2002</year>;<volume>23</volume>(<issue>1</issue>):<fpage>90</fpage>-<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr43-2150135112438107">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onoue</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Adachi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ichida</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Miyawaki</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Effective use of corticosteroid in a child with life-threatening plastic bronchitis after Fontan operation</article-title>. <source>Pediatr Int</source>. <year>2003</year>;<volume>45</volume>(<issue>1</issue>):<fpage>107</fpage>-<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr44-2150135112438107">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendoza Soto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Galletti</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gomez de Quero</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ramos Casado</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Velasco Bayon</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Plastic bronchitis: a case report and review of the literature</article-title>. <source>An Pediatr (Barc)</source>. <year>2005</year>;<volume>62</volume>(<issue>1</issue>):<fpage>72</fpage>-<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr45-2150135112438107">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Mallah</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Prabhakaran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chesrown</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Plastic bronchitis: resolution after heart transplantation</article-title>. <source>Pediatr Pulmonol</source>. <year>2011</year>;<volume>46</volume>(<issue>8</issue>):<fpage>824</fpage>-<lpage>825</lpage>.</citation>
</ref>
<ref id="bibr46-2150135112438107">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laubisch</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Mogayzel</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>WR</given-names>
</name>
</person-group>. <article-title>Treatment of plastic bronchitis by orthotopic heart transplantation</article-title>. <source>Pediatr Cardiol</source>. <year>2011</year>;<volume>32</volume>(<issue>8</issue>):<fpage>1193</fpage>-<lpage>1195</lpage>.</citation>
</ref>
<ref id="bibr47-2150135112438107">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bendayan</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Casaldaliga</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Castello</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Miro</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Herparin therapy and reversal of protein-losing enteropathy in a case with congenital heart disease</article-title>. <source>Pediatr Cardiol</source>. <year>2000</year>;<volume>21</volume>(<issue>3</issue>):<fpage>267</fpage>-<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr48-2150135112438107">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lortat-Jacob</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Grimaud</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Interferon-gamma binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule</article-title>. <source>FEBS Lett</source>. <year>1991</year>;<volume>280</volume>(<issue>1</issue>):<fpage>152</fpage>-<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr49-2150135112438107">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lortat-Jacob</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Grimaud</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Interferon-gamma C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-gamma, protect, relax the cytokine and regulate its activity</article-title>. <source>Cell Mol Biol</source>. <year>1991</year>;<volume>37</volume>(<issue>3</issue>):<fpage>253</fpage>-<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr50-2150135112438107">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvima</surname>
<given-names>IT</given-names>
</name>
<name>
<surname>Lappalainen</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hirvonen</surname>
<given-names>MR</given-names>
</name>
<etal/>
</person-group> <article-title>Heparin modulates the growth and adherence and augments the growth-inhibitory action of TNF-alpha on cultured human keratinocytes</article-title>. <source>J Cell Biochem</source>. <year>2004</year>;<volume>92</volume>(<issue>2</issue>):<fpage>372</fpage>-<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr51-2150135112438107">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rychik</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Piccoli</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure</article-title>. <source>Am J Cardiol</source>. <year>1991</year>;<volume>68</volume>(<issue>8</issue>):<fpage>819</fpage>-<lpage>821</lpage>.</citation>
</ref>
<ref id="bibr52-2150135112438107">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zellers</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Protein-losing enteropathy after the modified Fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement</article-title>. <source>Pediatr Cardiol</source>. <year>1996</year>;<volume>17</volume>(<issue>2</issue>):<fpage>115</fpage>-<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr53-2150135112438107">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thacker</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dodds</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> <article-title>Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation</article-title>. <source>Ann Thorac Surg</source>. <year>2010</year>;<volume>89</volume>(<issue>3</issue>):<fpage>837</fpage>-<lpage>842</lpage>.</citation>
</ref>
<ref id="bibr54-2150135112438107">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schumacher</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Cools</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>BH</given-names>
</name>
<etal/>
</person-group> <article-title>Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients</article-title>. <source>Pediatr Cardiol</source>. <year>2011</year>;<volume>32</volume>(<issue>7</issue>):<fpage>966</fpage>-<lpage>971</lpage>.</citation>
</ref>
<ref id="bibr55-2150135112438107">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mertens</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hagler</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Sauer</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Somerville</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gewillig</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Protein-losing enteropathy after the Fontan operation: an international multicenter study</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>1998</year>;<volume>115</volume>(<issue>5</issue>):<fpage>1063</fpage>-<lpage>1073</lpage>.</citation>
</ref>
<ref id="bibr56-2150135112438107">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meadows</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment</article-title>. <source>Cardiol Young</source>. <year>2011</year>;<volume>21</volume>(<issue>4</issue>):<fpage>363</fpage>-<lpage>377</lpage>.</citation>
</ref>
<ref id="bibr57-2150135112438107">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Rhodes</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Wernovsky</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Atrial pacing: an alternative treatment for protein-losing enteropathy after the Fontan operation</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2001</year>;<volume>121</volume>(<issue>3</issue>):<fpage>582</fpage>-<lpage>583</lpage>.</citation>
</ref>
<ref id="bibr58-2150135112438107">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vyas</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Driscoll</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Cabalka</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Cetta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Hagler</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>Results of transcatheter Fontan fenestration to treat protein losing enteropathy</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2007</year>;<volume>69</volume>(<issue>4</issue>):<fpage>584</fpage>-<lpage>589</lpage>.</citation>
</ref>
<ref id="bibr59-2150135112438107">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rychik</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rome</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>Late surgical fenestration for complications after the Fontan operation</article-title>. <source>Circulation</source>. <year>1997</year>;<volume>96</volume>(<issue>1</issue>):<fpage>33</fpage>-<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr60-2150135112438107">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobs</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Rychik</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Byrum</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Norwood</surname>
<given-names>WI</given-names>
</name>
</person-group>. <article-title>Protein-losing enteropathy after Fontan operation: resolution after baffle fenestration</article-title>. <source>Ann Thorac Surg</source>. <year>1996</year>;<volume>61</volume>(<issue>1</issue>):<fpage>206</fpage>-<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr61-2150135112438107">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mavroudis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Deal</surname>
<given-names>BJ</given-names>
</name>
</person-group>, <article-title>Backer CL, et al. 111 Fontan conversions with arrhythmia surgery: surgical lessons and outcomes</article-title>. <source>Ann Thorac Surg</source>. <year>2007</year>;<volume>84</volume>(<issue>5</issue>):<fpage>1457</fpage>-<lpage>1466</lpage>.</citation>
</ref>
<ref id="bibr62-2150135112438107">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinstein</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Extracardiac Fontan conversion, cryoablation, and pacemaker placement for patients with a failed Fontan</article-title>. <source>Semin Thorac Cardiovasc Surg</source>. <year>2005</year>;<volume>17</volume>(<issue>2</issue>):<fpage>170</fpage>-<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr63-2150135112438107">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marcelletti</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Hanley</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Mavroudis</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Revision of previous Fontan connections to total extracardiac cavopulmonary anastomosis: a multicenter experience</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2000</year>;<volume>119</volume>(<issue>2</issue>):<fpage>340</fpage>-<lpage>346</lpage>.</citation>
</ref>
<ref id="bibr64-2150135112438107">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Boucek</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>Heart transplantation for the failing Fontan circulation</article-title>. <source>Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu</source>. <year>2004</year>;<volume>7</volume>:<fpage>56</fpage>-<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr65-2150135112438107">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gamba</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Merlo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fiocchi</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Heart transplantation in patients with previous Fontan operations</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2004</year>;<volume>127</volume>(<issue>2</issue>):<fpage>555</fpage>-<lpage>562</lpage>.</citation>
</ref>
<ref id="bibr66-2150135112438107">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernstein</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Naftel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>114</volume>(<issue>4</issue>):<fpage>273</fpage>-<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr67-2150135112438107">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanter</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Mahle</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>RN</given-names>
</name>
<etal/>
</person-group> <article-title>Heart transplantation in children with a Fontan procedure</article-title>. <source>Ann Thorac Surg</source>. <year>2011</year>;<volume>91</volume>(<issue>3</issue>):<fpage>823</fpage>-<lpage>830</lpage>.</citation>
</ref>
<ref id="bibr68-2150135112438107">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamour</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Addonizio</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Galantowicz</surname>
<given-names>ME</given-names>
</name>
<etal/>
</person-group>. <article-title>Outcome after orthotopic cardiac transplantation in adults with congenital heart disease</article-title>. <source>Circulation</source>. <year>1999</year>:<volume>100</volume>(<issue>19 suppl</issue>):<fpage>II</fpage>-<lpage>200</lpage>-<fpage>II</fpage>-<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr69-2150135112438107">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brancaccio</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Carotti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>D’Argenio</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Michielon</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Parisi</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Protein-losing enteropathy after Fontan surgery: resolution after cardiac transplantation</article-title>. <source>J Heart Lung Transplant</source>. <year>2003</year>;<volume>22</volume>(<issue>4</issue>):<fpage>484</fpage>-<lpage>486</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>